Expert Interview
A second look: Discussing the potential of Orforglipron, a once daily oral GLP-1 receptor agonist, and the Phase 2 Study in obesity recently presented at ADA 2023.
Ticker(s): LLYInstitution: Penn Endocrinology Bucks County
- treats 250 patients with obesity
- attended ADA and saw the results from the Phase 2 trial in obesity recently presented at ADA
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
